The present invention relates to the use of VEGF antagonists and a novel anti-α5β1antibody for treating cancer and inhibiting angiogenesis and/or vascular permability,including inhibiting abnormal angiogenesis in diseases. The present inventionalso relates to compositions and kits comprising novel anti-α5β1antibodies and methods of making and using them.